The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Quantitative methylation profiles of multiple genes in patients with non-small cell lung cancer and its association with clinicopathological correlations Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
Aberrant methylation of p16 tumour suppresor gene and DAP kinase in nonsmall cell lung carcinomas Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
Clinical significance and functional roles of FoxM1 in non-small cell lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011
Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Transcriptional regulation of the human osteopontin promoter in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005
Distribution of BCL-2 gene expression and its prognostic value in non-small cell pulmonary cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002
Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006
HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Source: Eur Respir J 2009; 33: 127-133 Year: 2009